A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes

David M. Salerno, Gregory Granrud, Patricia Sharkey, Richard W Asinger, Morrison Hodges

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Abstract

The effectiveness of oral propafenone was evaluated for the treatment of ventricular premature complexes (VPCs) in 12 patients, using a singleblind, dose-ranging trial followed by a double-blind comparison with placebo, and then an open-label, long-term protocol. During dose ranging, 8 of 12 patients achieved ≥ 80 % suppression of total VPCs (mean 83%) (p < 0.01 vs single-blind placebo). Paired VPCs were suppressed ≥ 90 % and ventricular tachycardia was eliminated in 11 of the 12 patients (p < 0.01). The effectiveness of propafenone for treatment of VPCs was confirmed during the double-blind trial (p < 0.05 vs double-blind placebo) and during treatment for 6 months (p < 0.05 vs initial single-blind placebo). Propafenone prolonged the PR interval by 16% (p < 0.01 vs single-blind placebo) and the QRS interval by 18 % (p < 0.001). Left ventricular systolic performance decreased as assessed by 2-dimensional echocardiography (p < 0.01 vs single-blind placebo). Propafenone increased serum digoxin levels in 5 of 5 patients (mean increase of 83 %). Side effects included exacerbation of congestive heart failure (1 patient) and conduction abnormalities (2 patients). Thus, propafenone is effective for treatment of total and repetitive VPCs. Although generally well tolerated, the drug reduces left ventricular systolic function and atrioventricular conduction and increases serum digoxin levels.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalThe American Journal of Cardiology
Volume53
Issue number1
DOIs
StatePublished - Jan 1 1984

Bibliographical note

Funding Information:
From the Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota. This study was supported by a grant from the Knoll Pharmaceutical Company, Whippany, New Jersey. Manuscript received May 27, 1983; revised manuscript received September 28, 1983; accepted September 29, 1983.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes'. Together they form a unique fingerprint.

Cite this